Initial programmatic implementation of WHO option B in Botswana associated with increased projected MTCT

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 3, 2015, Pages 245-249

  Dryden Peterson, Scott ^a,b,c   Lockman, Shahin ^a,b,c   Zash, Rebecca ^b,d   Lei, Quonhong ^c   Chen, Jennifer Y ^e   Souda, Sajini ^f   Petlo, Chipo ^g   Dintwa, Eldah ^g   Lebelonyane, Refeletswe ^g   Mmalane, Mompati ^b   Shapiro, Roger L ^b,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF BOTSWANA   (Botswana)

^g Department of HIV AIDS Prevention and Care   (Botswana)

Author keywords

ART initiation; HIV 1; implementation science; Option B; PMTCT; sub Saharan Africa

Indexed keywords

NEVIRAPINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BOTSWANA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MATERNITY WARD; PRENATAL CARE; PRIORITY JOURNAL; SINGLE DRUG DOSE; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; DRUG UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; PROCEDURES; TRANSMISSION;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BOTSWANA; COHORT STUDIES; DRUG UTILIZATION; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84923699603     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000482     Document Type: Article

References (21)

1. Mofenson LM. Protecting the next generation-eliminating perinatal HIV-1 infection. N Engl J Med. 2010; 362: 2316-2318.
2. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Recommendations for a Public Heath Approach. Geneva, Switzerland: World Health Organization; 2010.
3. World Health Organization. Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Geneva, Switzerland: World Health Organization; 2012.
4. Centers for Disease C, Prevention. Impact of an innovative approach to prevent mother-to-child transmission of HIV-Malawi, July 2011-September 2012. MMWR Morb Mortal Wkly Rep. 2013; 62: 148-151.
5. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treatingand Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2013.
6. Tlale J, Keapoletswe K, Anderson MG, et al. Mother-to-child HIV transmission rate in Botswana-analysis of dried blood spot (DBS) results from the national PMTCT programme. Paper presented at: XVII Internataionl AIDS Conference, August 3-8, 2008; Mexico City.
7. Botswana Ministry of Health. Prevention of Mother-to-Child Transmission (PMTCT) of HIV: Pocket Guide. Gaborone, Botswana: Ministry of Health; 2011.
8. Botswana Ministry of Health. 2012 Botswana National HIV &AIDS Treatment Guidelines. Gaborone, Botswana: Ministry of Health; 2012.
9. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012; 206: 1695-1705.
10. Botswana Ministry of Health. Botswana 2008 National HIV/AIDS Guidelines, 1 November 2008 Edition. Gaborone, Botswana: Ministry of Health; 2008.
11. Rollins N, Mahy M, Becquet R, et al. Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in spectrum and other population-based models. Sex Transm Infect. 2012; 88 (suppl 2): i44-i51.
12. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010; 362: 2282-2294.
13. Dryden-Peterson S, Jayeoba O, Hughes MD, et al. Highly active antiretroviral therapy versus zidovudine for prevention of mother-tochild transmission in a programmatic setting, Botswana. J Acquir Immune Defic Syndr. 2011; 58: 353-357.
14. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA. 2006; 296: 794-805.
15. Dabis F, Bequet L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS. 2005; 19: 309-318.
16. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mere-Enfant. Lancet. 1999; 353: 786-792.
17. Kesho Bora Study G, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011; 11: 171-180.
18. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr. 2009; 52: 406-416.
19. Kuhn L, Aldrovandi GM, Sinkala M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med. 2008; 359: 130-141.
20. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002; 359: 1178-1186.
21. Ministry of Health. Botswana Country Update. Paper presented at: Regional EMTCT Stock-Taking Meeting 2014; Johannesburg, South Africa